Charles River Laboratories International, Inc. (CRL) Earnings Call Analysis

NYSE · Healthcare · Diagnostics & Research

21/25

Growth 4 Margin 4 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

21
Charles River Laboratories (CRL) Q2 2026: DSA Backlog Climbs to $1.97B as Book-to-Bill Hits 1.19x, Powering Margin Upside
August 05, 2026
15
Charles River Laboratories (CRL) Q1 2026: Margin Expansion Path Drives 500 Basis Point 2H Rebound
May 07, 2026
15
Charles River Laboratories (CRL) Q4 2025: DSA Bookings Jump to 1.12x as Biotech Funding Rebounds
February 24, 2026
12
Charles River Laboratories (CRL) Q3 2025: 7% Portfolio Divestiture Targets $0.30 EPS Accretion
November 05, 2025
16
Charles River (CRL) Q2 2025: DSA Net Book-to-Bill Climbs to 0.93, Signaling Demand Stabilization Path
August 06, 2025
18
Charles River Laboratories (CRL) Q1 2025: DSA Bookings Surge 20%, Signaling Demand Stabilization Amid Regulatory Shift
July 06, 2025

Browse all companies